Figure 1From: A randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of Candesartan on the insulin sensitivity on non diabetic, non hypertense subjects with dysglyce mia and abdominal obesity. "ARAMIA" title. Physiopathological mechanisms relating abdominal adiposity, angiotensin II, insulin resistance and cardiovascular events. For description see text.Foot note. FFA: Free Fatty Acids, FAS:, GDPH:, IL-6: Interleukine 6, IL1β: Interleukine 1β, TNFα: Tumoral Necrosis Factor α, AI: Angiotensin I, AII: Angiotensin II, ACE: Angiotensin Converting Enzime, eNOS: endothelial Nitric Oxide Sintase, CPKII: Creatinphosphokinase-II, IRS-1: Type 1 Insulin Soluble Receptor IRS-2: Tipe 2 Insulin Soluble Receptor, GLUT-4: Type 4 Glucose Membrane Trasnporter, MMP2: Matrix Metalloproteinase-2, NO: Nitric Oxide, UPC-2: Uncoupling Portein 2, PPARs: Peroxisome Proliferator-Activated Receptors, DM2: Tipe 2 Diabetes Mellitus, CVE: Cardiovascular Events, scater line: Inhibition or delay, filled line: Activation or increment.Back to article page